Skip to Content
Merck

B0515

Betamethasone 17-valerate

Synonym(s):

1,4-Pregnadiene-11β,17α,21-triol-9α-fluoro-16β-methyl-3,20-dione 17-valerate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17-valerate, 9α-Fluoro-16β-methylprednisolone 17-valerate, Betnovate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C27H37FO6
CAS Number:
2152-44-5
Molecular Weight:
476.58
UNSPSC Code:
12352200
NACRES:
NA.77
PubChem Substance ID:
24891523
MDL number:
MFCD00867446
Beilstein/REAXYS Number:
4240001
Form:
powder
Quality level:
200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

SNHRLVCMMWUAJD-QDHNOTTGSA-N

SMILES string

CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO

InChI

1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19?,20?,21-,24-,25-,26-,27-/m0/s1

form

powder

originator

Schering Plough

storage temp.

2-8°C

Quality Level

200

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Betamethasone 17-valerate is a synthetic glucocorticoid. It exhibitstherapeutic effects against various allergic and inflammatory skin diseases. Betamethasone 17-valerate also possesses anti-inflammatory properties.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000464374
0000464373
0000464373
0000464374
SLBS8916

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of five anti-inflammatory steroids on collagen and glycoaminoglycan synthessis in vitro
Saarni H, et al.
British Journal of Dermatology, 103(2), 167-173 (1980)
Atsuko Kamo et al.
Journal of dermatological science, 62(2), 91-97 (2011-04-05)
UV-based therapy has anti-pruritic effects in inflammatory skin diseases, such as atopic dermatitis and psoriasis. These anti-pruritic effects may be partly due to inhibition of intraepidermal nerve growth, but they have not been fully characterized. This study was performed to
L B Jensen et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 79(1), 68-75 (2011-06-15)
Treatment of skin diseases implies application of a drug to skin with an impaired epidermal barrier, which is likely to affect the penetration profile of the drug substance as well as the carrier into the skin. To elucidate this, the
Taner Senyiğit et al.
International journal of pharmaceutics, 403(1-2), 123-129 (2010-11-05)
The aim of this study was to evaluate the suitability of sodium-deoxycholate (Na-DOC) gels containing betamethasone-17-valerate (BMV) for topical application. The gels were characterized for rheological and textural properties. The in vitro flux of BMV from Na-DOC gels across rat
Christine Bangert et al.
Dermatology (Basel, Switzerland), 222(1), 36-48 (2010-12-15)
Topical pimecrolimus may maintain remissions of atopic dermatitis (AD) by inhibiting subclinical inflammation. To evaluate clinical and cytological effects of pimecrolimus in topical corticosteroid-treated and resolved AD lesions. Patients (n=67) with resolved AD lesions were randomized to 3-week double-blind treatment
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service